Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …

Purpose To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …

Background This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in
treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs) …

Highlights What are the main findings? Nirmatrelvir/Ritonavir, an oral treatment for COVID-
19, effectively reduces the risk of progressing to a more severe disease state for both the …

Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …

To evaluate the effect of Nirmatrelvir‐ritonavir therapy and coronavirus disease 2019
(COVID‐19) vaccination on clinical outcomes of severe acute respiratory syndrome …

Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

Introduction: Randomized, controlled trials of molnupiravir in real-world use during the
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …

Objective: The main goal of this study was to assess the potential clinical impact of an
outpatient administration of available antivirals including SOT, N/R, and MOL to COVID-19 …